US Dollar Index slips from its 18-month high
Brent fell below $98 a barrel as Gulf exports picked up, and bond yields in Europe and the US fell with it. France got the most relief, as the extra yield investors want for holding its 10-year debt over Germany's narrowed to about 1.3 percentage points from more than 1.5 on Friday.
The Euro, more than half the Dollar Index, has rebounded from Monday's low, its weakest since May 2025. Every other currency in the index has gained on the Dollar except the Yen and the Swiss Franc, the two that investors buy when they're nervous.
Investors are buying risk, and the S&P 500 has hit a record. The record is narrow. Nvidia (NVDA), Apple (AAPL) and Microsoft (MSFT) now make up more than 21% of the S&P 500, and the Russell 2000 of smaller companies is barely higher.
Part of Brent Crude Oil's fall is a Group of Seven (G7) release of 100 million barrels of emergency stocks over four months. That's about five days of what went through the Strait of Hormuz before the war.
On the charts
Monday's bar topped out just above 102.50, the highest since April 2025, and left a long upper wick. Tuesday's bar has gone back under 102.00 and below Monday's low.
The drop reached the 101.75 area, less than a fifth of the rally from the September 9 low near 98.60, and the index is trading near 101.85. Momentum indicators have broadly turned down since late September. The index is still well above its 50-day Exponential Moving Average (EMA) near 100.35.
DXY, daily chart
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Monnalisa shares delist from Euronext Growth Milan
Monnalisa’s delisting from trading on Euronext Growth Milan took effect today. The company is preparing a shareholder buyback process led by Modamet and Jafin Due for investors seeking to sell. Further details are due in coming days on the purchase window and a single settlement date for the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monnalisa S.p.A. published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
ICE brings futures trading to London’s $190 billion-a-day physical gold market
Updated: 3-ArriVent’s cancer drug failed to “significantly” delay disease progression, stock price plummeted
Updated stock data and added analyst comments in paragraphs 8 and 10 Christy Santhosh - Reuters, October 6 - ArriVent BioPharma (AVBP.O) announced on Tuesday that its oral therapy for a rare form of lung cancer failed to significantly delay disease progression in a late-stage clinical trial, causing the company's share price to plunge by nearly 60% in early trading. The therapy, firmonertinib, was tested in treatment-naïve advanced non-small cell lung cancer (NSCLC) patients carrying a gene mutation known as EGFR exon 20 insertion, which may promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC makes up around 85% of all lung cancer cases. An assessment by independent reviewers showed that ArriVent’s 240 mg dose therapy extended median progression-free survival to 11 months in the trial, compared to just 9.5 months for the chemotherapy group. CEO Bing Yao stated that the improvement in progression-free survival (i.e., the period during which a patient's cancer does not worsen or spread) was not "significant". "These disappointing results are not what we had hoped for, especially for patients who... are in urgent need of more effective treatment options." The company said it is reviewing the complete dataset to determine the most appropriate development path for firmonertinib, and no new safety signals were observed in the trial. BTIG analyst Jeet Mukherjee noted that the main reason the trial appears to have failed was the control group's performance exceeding expectations—their progression-free survival reached 9.5 months, when only 7.5 to 8 months was anticipated; firmonertinib’s 11-month result matched the expected range of 9 to 11 months. Additionally, firmonertinib is currently undergoing an advanced clinical trial in NSCLC patients with rare EGFR PACC mutations in their tumors. "This result is a significant setback for the exon 20 mutation treatment space, but the PACC program still has clinical support," said Clear Street analyst Kaveri Pohlman. The therapy has been approved in China for NSCLC patients carrying specific mutations. (To aid non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of these translated texts and they are provided for reader convenience only. Reuters is not responsible for any damages or losses arising from the use of automated translation features.)
BUZZ - Sphere Entertainment shares drop as BTIG lowers price target, citing slowing bookings
On October 6th, Sphere Entertainment (SPHR.N) shares fell over 6% to $104.04. BTIG lowered its price target from $190 to $160, which still represents a 44% upside from the latest closing price. The broker reduced its third-quarter revenue forecast for the Sphere Experience business from $123 millions to $110 millions, and its fourth-quarter forecast from $164 millions to $148 millions, both below Wall Street estimates of $123 millions and $164 millions. Based on its analysis of ticket sales, a slowdown in “The Wizard of Oz” bookings at the end of Q3, and booking trends in early October, it expects reduced ticket sales and lower revenue per performance. Among 13 brokers, 11 rate the stock as “buy” or higher, and 2 rate it as “hold,” with a median target price of $178.50, according to data compiled by LSEG. Including daily price fluctuations, the stock is up 10.50% year-to-date.
Crypto prices
More
